Caris Life Sciences (CAI) fell about 6% to $18.34 in the latest session as traders focused on balance-sheet headlines and the after-effects of a recently disclosed financing. The move comes as the market digests higher leverage and the cost of capital implied by the company’s new senior secured credit facilities.

On April 1, 2026, Caris entered into a new credit agreement with lenders consisting of funds managed by Blue Owl Capital and Blackstone, featuring (i) a $400 million initial term loan funded at closing, (ii) a committed delayed-draw term loan facility of up to $300 million, and (iii) an uncommitted incremental facility up to $500 million. The initial term facility matures in April 2031, while the delayed-draw facility is available through August 2027 and is restricted for use in permitted acquisitions. The loans carry interest at the company’s option of base rate or term SOFR, plus a margin; for the initial and delayed-draw term loans the margin is 5.00% over term SOFR or 4.00% over base rate, a level that can translate into a meaningful step-up in cash interest expense depending on prevailing rates. The agreement also includes a minimum qualified cash requirement of $50 million tested quarterly and is secured by substantially all personal property, including pledges of subsidiary equity.

Even if the facility improves liquidity and provides capacity for acquisitions, the pricing and structure can pressure sentiment in a risk-off tape: higher variable-rate debt increases sensitivity to interest rates, and secured credit agreements can add covenant and collateral constraints that equity investors sometimes discount quickly. Caris also used proceeds from the initial term loan to repay and terminate its prior credit agreement, resetting its capital structure while keeping attention on financing-driven catalysts rather than operating results.

Key near-term drivers are (1) any drawdown on the $300 million delayed-draw facility and the specific acquisition targets tied to those draws, (2) updates on cash balances versus the $50 million minimum qualified cash requirement, and (3) any changes to forward-looking commentary on profitability and free cash flow as interest expense flows through results. Investors will also watch for additional SEC filings that clarify detailed terms in exhibits expected to be filed with the company’s quarterly report for the period ending March 31, 2026.